These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31636389)

  • 1. PREX1 drives spontaneous bone dissemination of ER+ breast cancer cells.
    Clements ME; Johnson RW
    Oncogene; 2020 Feb; 39(6):1318-1334. PubMed ID: 31636389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling.
    Liu HJ; Ooms LM; Srijakotre N; Man J; Vieusseux J; Waters JE; Feng Y; Bailey CG; Rasko JE; Price JT; Mitchell CA
    J Biol Chem; 2016 Aug; 291(33):17258-70. PubMed ID: 27358402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Role for TGFβ Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression.
    Cheng JN; Frye JB; Whitman SA; Kunihiro AG; Pandey R; Funk JL
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.
    Chiu JH; Wen CS; Wang JY; Hsu CY; Tsai YF; Hung SC; Tseng LM; Shyr YM
    J Transl Med; 2017 May; 15(1):97. PubMed ID: 28472954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERRα Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response.
    Bouchet M; Lainé A; Boyault C; Proponnet-Guerault M; Meugnier E; Bouazza L; Kan CWS; Geraci S; El-Moghrabi S; Hernandez-Vargas H; Benetollo C; Yoshiko Y; Duterque-Coquillaud M; Clézardin P; Marie JC; Bonnelye E
    Cancer Res; 2020 Jul; 80(13):2914-2926. PubMed ID: 32366476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.
    Vargas G; Bouchet M; Bouazza L; Reboul P; Boyault C; Gervais M; Kan C; Benetollo C; Brevet M; Croset M; Mazel M; Cayrefourcq L; Geraci S; Vacher S; Pantano F; Filipits M; Driouch K; Bieche I; Gnant M; Jacot W; Aubin JE; Duterque-Coquillaud M; Alix-Panabières C; Clézardin P; Bonnelye E
    Oncogene; 2019 Feb; 38(7):950-964. PubMed ID: 30478447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transactivation of SOX5 by Brachyury promotes breast cancer bone metastasis.
    Chen M; Zou S; He C; Zhou J; Li S; Shen M; Cheng R; Wang D; Zou T; Yan X; Huang Y; Shen J
    Carcinogenesis; 2020 Jul; 41(5):551-560. PubMed ID: 31713604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
    Dhimolea E; de Matos Simoes R; Kansara D; Weng X; Sharma S; Awate P; Liu Z; Gao D; Mitsiades N; Schwab JH; Chen Y; Jeselsohn R; Culhane AC; Brown M; Georgakoudi I; Mitsiades CS
    Cancer Res; 2021 Jan; 81(2):371-383. PubMed ID: 32859606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
    Barrio-Real L; Benedetti LG; Engel N; Tu Y; Cho S; Sukumar S; Kazanietz MG
    Breast Cancer Res; 2014 Sep; 16(5):441. PubMed ID: 25248717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bone microenvironment invigorates metastatic seeds for further dissemination.
    Zhang W; Bado IL; Hu J; Wan YW; Wu L; Wang H; Gao Y; Jeong HH; Xu Z; Hao X; Lege BM; Al-Ouran R; Li L; Li J; Yu L; Singh S; Lo HC; Niu M; Liu J; Jiang W; Li Y; Wong STC; Cheng C; Liu Z; Zhang XH
    Cell; 2021 Apr; 184(9):2471-2486.e20. PubMed ID: 33878291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.
    Tulotta C; Lefley DV; Freeman K; Gregory WM; Hanby AM; Heath PR; Nutter F; Wilkinson JM; Spicer-Hadlington AR; Liu X; Bradbury SMJ; Hambley L; Cookson V; Allocca G; Kruithof de Julio M; Coleman RE; Brown JE; Holen I; Ottewell PD
    Clin Cancer Res; 2019 May; 25(9):2769-2782. PubMed ID: 30670488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
    Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z
    BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
    Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fam20C Regulates Bone Resorption and Breast Cancer Bone Metastasis through Osteopontin and BMP4.
    Zuo H; Yang D; Wan Y
    Cancer Res; 2021 Oct; 81(20):5242-5254. PubMed ID: 34433585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
    McAuley JR; Bailey KM; Ekambaram P; Klei LR; Kang H; Hu D; Freeman TJ; Concel VJ; Hubel NE; Lee JL; Klei HB; Cheng J; Sekar P; Bridwell RE; Covic L; Lucas PC; McAllister-Lucas LM
    Oncogene; 2019 Dec; 38(49):7384-7398. PubMed ID: 31420608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour but not stromal expression of β3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer.
    Carter RZ; Micocci KC; Natoli A; Redvers RP; Paquet-Fifield S; Martin AC; Denoyer D; Ling X; Kim SH; Tomasin R; Selistre-de-Araújo H; Anderson RL; Pouliot N
    J Pathol; 2015 Apr; 235(5):760-72. PubMed ID: 25430721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer cells expressing cancer-associated sialyl-Tn antigen have less capacity to develop osteolytic lesions in a mouse model of skeletal colonization.
    Fujita R; Hamano H; Kameda Y; Arai R; Shimizu T; Ota M; Sato D; Kobayashi H; Iwasaki N; Takahata M
    Clin Exp Metastasis; 2019 Dec; 36(6):539-549. PubMed ID: 31595388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
    Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
    Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LCC15-MB: a vimentin-positive human breast cancer cell line from a femoral bone metastasis.
    Thompson EW; Sung V; Lavigne M; Baumann K; Azumi N; Aaron AD; Clarke R
    Clin Exp Metastasis; 1999 May; 17(3):193-204. PubMed ID: 10432004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.
    Absil L; Journé F; Larsimont D; Body JJ; Tafforeau L; Nonclercq D
    BMC Cancer; 2020 Jul; 20(1):640. PubMed ID: 32650752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.